Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Company Overview

Asterias Biotherapeutics, Inc. was a biotechnology company focused on developing regenerative medicine and immunotherapy products derived from human embryonic stem cells. Its research programs were aimed primarily at treating conditions involving the central nervous system and at developing cellular therapies for cancer.

The company’s lead program, AST-OPC1, consisted of oligodendrocyte progenitor cells intended to support the repair of damaged spinal cord tissue. Asterias also developed AST-VAC2, an investigational cancer immunotherapy based on dendritic cells designed to stimulate an immune response against tumor-associated antigens.

Asterias conducted clinical development activities in the United States and worked with research and commercial partners in advancing its programs. In 2019, BioTime, Inc. completed an acquisition of Asterias, after which Asterias operated as a wholly owned subsidiary and its standalone public-company operations ended. The company’s programs and assets subsequently became part of the broader regenerative medicine activities associated with BioTime, now known as Lineage Cell Therapeutics.

Key Stats

• Today's Range: $0.0020 to $0.0020
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $2.05
• Volume: 1,000 shs
• Average Volume: 136,653 shs
• Market Capitalization: $111.32 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/28/2017
• Today: 10/15/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:AST
• Previous Symbol: NYSEMKT:AST
• CIK: N/A
• Web: asteriasbiotherapeutics.com
• Phone: +1-510-4563805
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,659,000
• Free Float: N/A
• Market Cap: $111.32 thousand
• Optionable: Not Optionable
• Beta: N/A